PRIMARY STUDY

A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy

Key Findings:  In the group receiving saxagliptin as add-on therapy for diabetic kidney disease. levels of liver-type fatty acid-binding protein (uL-FABP) were higher, but not significantly